Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical... see more

Current News (NDAQ:MCRB)

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst(TM) Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

GlobeNewswire 8 days ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswire November 24, 2025

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 5, 2025

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

GlobeNewswire October 30, 2025

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

GlobeNewswire October 29, 2025

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

GlobeNewswire October 14, 2025

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

GlobeNewswire September 23, 2025

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 27, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire August 6, 2025
View More News ››

Opinion & Analysis (NDAQ:MCRB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MCRB)

Ser 155 phase 2 funding

Positives so far (guessing) 1) CRO to be used, it should be more efficient 2) trial expected to be started soon 3) funding should be...
Napcoo - September 24, 2025

RE:Now it's time to accumulate @78 cents

Q4 earnings says as a result, we have confidence that we will ultimately achieve our goal of VOWST becoming a foundational therapy...
Napcoo - March 28, 2024

Now it's time to accumulate @78 cents

$225 mln due if target milestone reached for the $575 mln deal, $175 mln upfront, $125 mln FDA approved, latest updates to reach sales...
Napcoo - March 28, 2024

Price

In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will...
IvanIvan - April 27, 2023

Maybe a chance to accumulate

Below 5 again. Maybe right cap on approval is between 800 - 900 million? 
hoffbag - January 15, 2023

Popping now!

Target valuation getting closer. 
hoffbag - October 31, 2022
View more Bullboard ››

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »

Podcasts